The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)
Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
Anidulafungin is an antifungal agent of the echinocandin class which is highly active in
vitro against fluconazole resistant Candida species. The efficacy of anidulafungin has
demonstrated in various animal models of fluconazole-resistant mucosal disease; as well as,
in Phase 2 Esophageal Candidiasis studies. This study is intended to offer patients with FRMC
an alternate therapy with amphotericin B or with other agents whose efficacy and/or safety
are inadequate in the treatment of this disease.